| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| Other Sizes |
| Targets |
MHC class I molecules and HBV-specific T-cell receptors. Hepatitis B Virus Core 128-140 is an immunodominant epitope derived from the HBV core antigen that is presented by MHC class I molecules to cytotoxic T lymphocytes (CTLs). The peptide sequence represents a region of the HBV core protein known to be involved in immunological processes, making it a valuable reagent for fundamental and applied research into viral pathogenesis, immune response mapping, and the development of diagnostic tools. It aids in detailed analysis of antibody binding sites and T-cell epitopes within the HBV core antigen.
|
|---|---|
| ln Vitro |
In vitro, Hepatitis B Virus Core 128-140 is used to stimulate HBV-specific T cells in T-cell activation assays. The peptide binds to MHC class I molecules and is recognized by TCRs on HBV-specific CTLs, leading to T cell activation, proliferation, and cytokine production. It is commonly employed in immunoassays such as ELISA, western blotting, or peptide microarrays to identify and characterize specific B-cell or T-cell epitopes. The peptide's defined sequence ensures specificity and reproducibility in immunological assays.
|
| ln Vivo |
In vivo, Hepatitis B Virus Core 128-140 is used in mouse models to study T-cell responses to HBV infection and vaccination. Administration of the peptide (typically with adjuvant) induces antigen-specific CD8+ T-cell responses in appropriate MHC-matched mice. The peptide can be used as an immunogen for generating polyclonal or monoclonal antibodies specific to the HBV core region. It is also utilized in adoptive transfer experiments to study T-cell expansion, differentiation, and memory formation following immunization or viral challenge.
|
| Enzyme Assay |
In vitro peptide-MHC binding assays for Hepatitis B Virus Core 128-140 measure the peptide's affinity for MHC class I molecules. The assay uses purified MHC molecules (or cell lines expressing appropriate MHC alleles) and fluorescently labeled reference peptides. Varying concentrations of the peptide are incubated with MHC molecules and beta2-microglobulin. After equilibration, bound peptide is detected by ELISA or fluorescence polarization. The peptide's binding affinity (IC50 or Kd) is calculated from competition curves. Alternatively, T2 cell lines are used to measure peptide-MHC stabilization by flow cytometry.
|
| Cell Assay |
In vitro T-cell activation assays using Hepatitis B Virus Core 128-140 are performed with splenocytes or purified CD8+ T cells from HBV-immune or TCR transgenic mice. Cells are cultured with varying concentrations of the peptide (typically 0.001-10 microg/mL) for 2-6 hours in the presence of brefeldin A or monensin for cytokine detection. T-cell activation is measured by intracellular cytokine staining (IFN-gamma, TNF-alpha, IL-2) followed by flow cytometry. Alternatively, ELISPOT assays are used to enumerate peptide-specific IFN-gamma-producing cells. CFSE dilution assays measure peptide-induced T-cell proliferation after 3-5 days of culture.
|
| Animal Protocol |
In vivo mouse studies with Hepatitis B Virus Core 128-140 are conducted in appropriate MHC-matched mice (e.g., H-2d or H-2b strains depending on the specific epitope). For immunization, mice receive the peptide (typically 10-100 microg) emulsified in adjuvant (e.g., CFA, IFA, or CpG) via subcutaneous or intraperitoneal injection. For T-cell tracking, HBV-specific TCR transgenic T cells can be labeled with CFSE or a cell tracer and adoptively transferred into recipient mice. Mice are then immunized with peptide or infected with HBV. Spleen and lymph nodes are harvested for flow cytometric analysis of T-cell expansion, activation, and differentiation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Hepatitis B Virus Core 128-140 are characteristic of peptide antigens. With a molecular weight of 1406.63, the peptide is soluble in water and DMSO. It is typically stored as a powder at -20degC, protected from light and moisture. When stored in solution at -80degC, it should be used within 6 months; at -20degC, within 1 month. As a research peptide, pharmacokinetic studies are not typically performed as it is used as an antigen rather than a therapeutic agent.
|
| Toxicity/Toxicokinetics |
Hepatitis B Virus Core 128-140 is intended for research use only and is not for human therapeutic use. As a short peptide antigen, it is generally well-tolerated in mouse studies at immunogenic doses. Standard safety precautions for handling peptides apply. No significant toxicity has been reported in the literature for this research peptide. The compound is not approved for clinical use.
|
| Additional Infomation |
Hepatitis B Virus Core 128-140 is a research-grade synthetic peptide used in immunology and virology research. It is a synthetic peptide fragment corresponding to amino acids 128 to 140 of the HBV core antigen with the sequence TPPAYRPPNAPIL. The peptide is instrumental in research focusing on viral replication and immune response, providing insights into the virus's interaction with host cells. It is used for epitope mapping, immunogenicity studies, diagnostic assay development, peptide-structure and function studies, and antibody production. Not approved for clinical use.
|
| Molecular Formula |
C66H103N17O17
|
|---|---|
| Molecular Weight |
1405.77
|
| Exact Mass |
1405.771
|
| CAS # |
160015-13-4
|
| PubChem CID |
24868193
|
| Sequence |
Thr-Pro-Pro-Ala-Tyr-Arg-Pro-Pro-Asn-Ala-Pro-Ile-Leu
Sequence Shortening |
| Appearance |
White to off-white solid powder
|
| LogP |
-4
|
| Hydrogen Bond Donor Count |
14
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
33
|
| Heavy Atom Count |
100
|
| Complexity |
3000
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
C(N1CCC[C@H]1C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C)C(N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(=O)O)CC(C)C)=O)([C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC([C@@H]1CCCN1C([C@@H]1CCCN1C(=O)[C@@H](N)[C@H](O)C)=O)=O)CC1C=CC(O)=CC=1)=O
|
| InChi Key |
ARMRKPQGEVPVSP-MMKKQSJESA-N
|
| InChi Code |
InChI=1S/C66H103N17O17/c1-8-35(4)52(59(93)77-44(65(99)100)31-34(2)3)78-58(92)47-18-10-26-79(47)60(94)37(6)73-54(88)43(33-50(67)86)76-57(91)46-17-12-28-81(46)62(96)48-19-13-29-82(48)61(95)41(15-9-25-71-66(69)70)74-55(89)42(32-39-21-23-40(85)24-22-39)75-53(87)36(5)72-56(90)45-16-11-27-80(45)63(97)49-20-14-30-83(49)64(98)51(68)38(7)84/h21-24,34-38,41-49,51-52,84-85H,8-20,25-33,68H2,1-7H3,(H2,67,86)(H,72,90)(H,73,88)(H,74,89)(H,75,87)(H,76,91)(H,77,93)(H,78,92)(H,99,100)(H4,69,70,71)/t35-,36-,37-,38+,41-,42-,43-,44-,45-,46-,47-,48-,49-,51-,52-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S,3S)-2-[[(2S)-1-[(2S)-2-[[(2S)-4-amino-2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7114 mL | 3.5568 mL | 7.1135 mL | |
| 5 mM | 0.1423 mL | 0.7114 mL | 1.4227 mL | |
| 10 mM | 0.0711 mL | 0.3557 mL | 0.7114 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
